Novel K+ Channel Targets in Atrial Fibrillation Drug Development – Where Are We?

El-Haou, S.; Ford, J.; Milnes, J.  Journal of Cardiovascular Pharmacology. 2015, 66 (5), 412-431


View
Recommended Publications
Latest Publications
Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions

Derek J. Leishman, Jessica Brimecombe, William Crumb, Simon Hebeisen, Steve Jenkinson, Peter J. Kilfoil, Hiroshi Matsukawa, Karim Melliti, Yusheng Qu, Journal of Pharmacological and Toxicological Methods, Volume 128, 2024, 107524, ISSN 1056-8719. DOI: 10.1007/978-3-031-52197-3

Copyright prevents linking to the article.

Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity

Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50

View All
Celebrating positive male role models: International Men's Day 2024
Assessing the Variability of hERG Data Generated Using a Mock Action Potential Waveform and Automated Patch Clamp Platforms
View All
Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.
Contact us for a quote or discussion
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram